A Phase Ib Study of Selatinib Ditosilate Tablets in Patients With Advanced Breast Cancer
Brief Description:

This study is designed to evaluate the safety and tolerability of oral Selatinib Ditosilate Tablets, and explore the maximum tolerated dose (MTD) and dose-limiting toxicity in patients with advanced breast cancer.
Advanced Breast Cancer
DRUG: selatinib ditosilate tablets
Dose-limiting toxicity(DLT), 21 days|Maximum tolerated dose(MTD), 21 days
Pharmacokinetics, Selatinib Ditosilate pharmacokinetic parameters , include AUC, Cmax, Tmax, and t1/2, 21 days|Pharmacodynamics, The response of Salatinib Ditosilate on tumor measured by CT or MRI., 7 weeks
1. To evaluate the safety and tolerability of oral Selatinib Ditosilate Tablets, and explore the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT).
2. To determine the pharmacokinetic profile of single and multi oral Selatinib Ditosilate Tablets .
3. To determine preliminary dose and regimen for phase II study of oral Selatinib Ditosilate Tablets.
4. To assess preliminary antitumor activity .